Your browser doesn't support javascript.
loading
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
Vacca, Michele; Kamzolas, Ioannis; Harder, Lea Mørch; Oakley, Fiona; Trautwein, Christian; Hatting, Maximilian; Ross, Trenton; Bernardo, Barbara; Oldenburger, Anouk; Hjuler, Sara Toftegaard; Ksiazek, Iwona; Lindén, Daniel; Schuppan, Detlef; Rodriguez-Cuenca, Sergio; Tonini, Maria Manuela; Castañeda, Tamara R; Kannt, Aimo; Rodrigues, Cecília M P; Cockell, Simon; Govaere, Olivier; Daly, Ann K; Allison, Michael; Honnens de Lichtenberg, Kristian; Kim, Yong Ook; Lindblom, Anna; Oldham, Stephanie; Andréasson, Anne-Christine; Schlerman, Franklin; Marioneaux, Jonathon; Sanyal, Arun; Afonso, Marta B; Younes, Ramy; Amano, Yuichiro; Friedman, Scott L; Wang, Shuang; Bhattacharya, Dipankar; Simon, Eric; Paradis, Valérie; Burt, Alastair; Grypari, Ioanna Maria; Davies, Susan; Driessen, Ann; Yashiro, Hiroaki; Pors, Susanne; Worm Andersen, Maja; Feigh, Michael; Yunis, Carla; Bedossa, Pierre; Stewart, Michelle; Cater, Heather L.
Affiliation
  • Vacca M; TVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK. michele.vacca@uniba.it.
  • Kamzolas I; Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy. michele.vacca@uniba.it.
  • Harder LM; Laboratory of Liver Metabolism and MASLD, Roger Williams Institute of Hepatology, London, UK. michele.vacca@uniba.it.
  • Oakley F; TVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Trautwein C; European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, UK.
  • Hatting M; Research and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.
  • Ross T; Newcastle Fibrosis Research Group, Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Bernardo B; Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Oldenburger A; Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.
  • Hjuler ST; Internal Medicine research Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA.
  • Ksiazek I; Internal Medicine research Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA.
  • Lindén D; CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
  • Schuppan D; Research and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.
  • Rodriguez-Cuenca S; Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland.
  • Tonini MM; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.
  • Castañeda TR; Division of Endocrinology, Department of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Kannt A; Institute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg University Medical Center, Mainz, Germany.
  • Rodrigues CMP; TVP Lab, WT/MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
  • Cockell S; Luxembourg Institute of Health, Translational Medicine Operations Hub, Dudelange, Luxembourg.
  • Govaere O; R&D Diabetes & Portfolio Innovation and Excellence, Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt, Germany.
  • Daly AK; R&D Diabetes, Sanofi-Aventis Deutschland GmbH, Industriepark Hoechst, Frankfurt, Germany.
  • Allison M; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Innovation Center TheraNova and Goethe University, Frankfurt, Germany.
  • Honnens de Lichtenberg K; Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
  • Kim YO; Bioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Lindblom A; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Oldham S; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Andréasson AC; Liver Unit, Cambridge University Hospitals NHS Foundation Trust & Cambridge NIHR Biomedical Research Centre, Cambridge, UK.
  • Schlerman F; Research and Early Development, Novo Nordisk A/S, Måløv, Copenhagen, Denmark.
  • Marioneaux J; Institute of Translational Immunology and Research Center for Immunotherapy, Johannes Gutenberg University Medical Center, Mainz, Germany.
  • Sanyal A; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.
  • Afonso MB; Bioscience Metabolism, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gaithersburg, MD, USA.
  • Younes R; Bioscience Cardiovascular, Research and Early Development Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca BioPharmaceuticals R&D, Gothenburg, Sweden.
  • Amano Y; Inflammation and Immunology Research Unit, Pfizer Worldwide Research and Development, Cambridge, MA, USA.
  • Friedman SL; Fleur De Lis Holdings 10201 Dakins Dr. Richmond, Richmond, VA, USA.
  • Wang S; Department of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA.
  • Bhattacharya D; Research Institute for Medicines, Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
  • Simon E; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Paradis V; Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.
  • Burt A; Research, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Grypari IM; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Davies S; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Driessen A; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Yashiro H; Global Computational Biology and Digital Sciences, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
  • Pors S; Department of Imaging and Pathology, Université Paris Diderot and Hôpital Beaujon, Paris, France.
  • Worm Andersen M; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Feigh M; Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
  • Yunis C; Department of Pathology, Aretaeion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
  • Bedossa P; Department of Cellular Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
  • Stewart M; Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
  • Cater HL; Department of Molecular Imaging, Pathology, Radiotherapy, Oncology. Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
Nat Metab ; 6(6): 1178-1196, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38867022
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Disease Models, Animal / Non-alcoholic Fatty Liver Disease Limits: Animals / Humans / Male Language: En Journal: Nat Metab Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Disease Models, Animal / Non-alcoholic Fatty Liver Disease Limits: Animals / Humans / Male Language: En Journal: Nat Metab Year: 2024 Document type: Article Affiliation country: Country of publication: